期刊文献+

Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer 被引量:2

Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer
下载PDF
导出
摘要 The US Preventive Services Task Force (USPSTF) analyzed the benefits and harms of prostate specific antigen (PSA)- based screening for prostate cancer (PCa). The Grade 'D' recommendation of the USPSTF was based mainly on the Prostate, Lung, Colorectal, and Ovarian (PLCO) study in the United States. That result showed only a small reduction in PCa mortality. However, the data from the International Agency for Research on Cancer (IARC) iUustrated the PCa mortality rate (MR) decreased marked. To avoid the over-diagnosis and over-treatment, the American Cancer Society has changed its strategy and updated its guidance. The USPSTF neglected the aggressive PCa accounted for more then 30% of all PCa. Highly aggressive PCa can be diagnosed by PSA screening combined with Gleason grade. We hope that the USPSTF changes the 'D' recommendation for PSA screening. The US Preventive Services Task Force (USPSTF) analyzed the benefits and harms of prostate specific antigen (PSA)- based screening for prostate cancer (PCa). The Grade 'D' recommendation of the USPSTF was based mainly on the Prostate, Lung, Colorectal, and Ovarian (PLCO) study in the United States. That result showed only a small reduction in PCa mortality. However, the data from the International Agency for Research on Cancer (IARC) iUustrated the PCa mortality rate (MR) decreased marked. To avoid the over-diagnosis and over-treatment, the American Cancer Society has changed its strategy and updated its guidance. The USPSTF neglected the aggressive PCa accounted for more then 30% of all PCa. Highly aggressive PCa can be diagnosed by PSA screening combined with Gleason grade. We hope that the USPSTF changes the 'D' recommendation for PSA screening.
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2013年第2期218-220,I0006,共4页 亚洲男性学杂志(英文版)
  • 相关文献

参考文献5

二级参考文献40

  • 1Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D et al.; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-9.
  • 2Mettlin C J, Murphy GP, Ho R, Menck HR. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer 1996; 77: 2162-6.
  • 3SchrSder FH, Hugosson J, Roobol M J, Tammela TL, Ciatto S et al. ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.
  • 4Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-32.
  • 5BilI-Axerson A, Holmberg L, Filen F, Ruutu M, Garmo H et al. Scandinavian Prostate Cancer Group Study Number 4. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial./Natl Cancer Inst. 2008; 100: 1144-54.
  • 6Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-23.
  • 7Catatona W.I, Smith DS, Ratliff TL, Dodds KM, Copten DE et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324:1156-61.
  • 8.lemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA CancerJ Clin 2010; 60: 277-300.
  • 9Greene KL, Albertsen PC, Babaian R J, Carter HB, Gann PH et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009; 182: 2232-41.
  • 10Vignati G, Giovanelli L. Standardization of PSA measures: a reappraisal and an experience with WHO calibration of Beckman Coulter Access Hybritech total and free PSA. Int J Biol Markers 2007; 22: 295-301.

共引文献46

同被引文献5

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部